Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195299 · ClinicalTrials.gov registry record
Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck
A clinical trial of Squamous Cell Carcinoma, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT00195299: Completed study of Squamous Cell Carcinoma, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00195299 is a study of Squamous Cell Carcinoma that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 20 participants, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00195299, a study of Squamous Cell Carcinoma, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their specific disease. The primary objective of this study is to identify biomarkers of temsirolimus activity.
Conditions Studied
Interventions
- DRUG Temsirolimus
Study Locations (1)
Louisiana
- - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-02 |
What the finished NCT00195299 record still lists
NCT00195299 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 104-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Temsirolimus is the first listed.
NCT00195299 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT00195299 about?
NCT00195299 is a clinical study titled "Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck". This is an open-label, exploratory, biomarker study of intravenous temsirolimus given once weekly for 3 weeks to newly diagnosed, advanced stage head and neck cancer subjects prior to beginning their standard therapy for their specific disease. The primary objective of this study is to identify biom...
What is the current status of trial NCT00195299?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2005-04. Estimated completion is 2007-02.
What conditions does trial NCT00195299 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma.
What interventions are being tested in trial NCT00195299?
The interventions under investigation include: Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00195299?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00195299 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00195299's enrollment target sits among peer trials
20 40th of 47 higher than 6 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
RECRUITING · NA
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
RECRUITING · Phase 1
-
Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain
RECRUITING · NA
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia